A Phase 2 interventional study of TAK-755 in Thrombotic Thrombocytopenic Purpura (TTP), sponsored by Takeda. Completed at 22 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda — 3 open to participants now, 4 under way, 1 of them phase 3. Purpura, Thrombotic Thrombocytopenic · Takeda.
Among the 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda, this one is the only one that started in 2023, is one of 2 in phase 2, and was the 6th registered.
67 studies on the registry are indexed under Purpura, Thrombotic Thrombocytopenic; 18 are open to participants now.
Browse Purpura, Thrombotic Thrombocytopenic studies →3 of the 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda are open now, in 4 countries. Recruiting first, the newest first:
Takeda · Sites in Germany, Poland
Takeda · Sites in Austria, Germany
Takeda · Sites in Japan
By country, each count listing its studies:
Of the 16 Purpura, Thrombotic Thrombocytopenic studies recruiting now, 12 (75%) set no upper age limit and 1 (6%) stops at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2023.
This study's enrollment of 29 is close to the median of 30 across 34 interventional studies indexed under Purpura, Thrombotic Thrombocytopenic.
Median enrollment 29 across the 5 interventional studies, 46 across the 4 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
1 of the studies in Purpura, Thrombotic Thrombocytopenic by Takeda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04683003Phase 3TakedaA Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura | 2027-03-16 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main aim of this study is to determine the percentage of participants with a clinical (Part 1) or platelet (Part 2) response without plasma exchange during the study. Participants who have an acute attack of iTTP will receive TAK-755 and immunosuppressive therapy during their stay at the hospital until they achieve a clinical response in Part 1 or platelet response in Part 2. Participants will also be treated with TAK-755 for an additional time of up to 6 weeks after the acute phase. In total, participants will stay in the study for approximately 3 months.
This study consists of 2-parts. Part 1 is a double-blind, randomized study in which participants were randomized 1:1, in a blinded fashion, into 2 TAK-755 dose groups. Part 1, randomization was stratified based on whether the participant had received pre-study PEX and on the participant's Glasgow Coma Scale. Part 2 is an open-label study in which participants with iTTP experiencing an acute iTTP episode will be enrolled and assigned to a single-arm treatment.
Key Inclusion Criteria (Part 1 and Part 2)
Key Exclusion Criteria (Part 1 and Part 2)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-755 Dose 1, IV infusion, in the acute phase until clinical response is achieved. All participants achieving clinical response will receive TAK-755 at Dose 2, for up to 6 weeks during the post-acute phase.
Biological: TAK-755
TAK-755 Dose 2, IV infusion, in the acute phase until clinical response is achieved. All participants achieving clinical response will receive TAK-755 at Dose 2, for up to 6 weeks during the post-acute phase.
Biological: TAK-755
TAK-755 Dose 3, IV infusion, in the acute phase until 48-hour platelet response is achieved. All participants achieving platelet response will receive TAK-755 at Dose 2, 4 times per week for Week 1 and 3 times per week for Week 2 and 3 during the post-acute phase based on investigator judgement as high-risk for developing iTTP recurrence.
Biological: TAK-755
TAK-755 IV infusion
Also known as: rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930
Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Event of Special Interest (AESIs) After Receiving any Dose of Investigational Product (IP)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. SAE: Signs, symptoms or outcomes which results in death, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, results in a congenital abnormality/birth defect, or is an important medical event. Adverse events of special interest include major thrombotic events and treatment-related bleeding events.
Time frame: Through study completion, approximately 12 weeks
Part 1: Achievement of Clinical Response Without On-Study Plasma Exchange (PEX)
Clinical response is defined as normalization of platelets and no clinical evidence of new or progressive ischemic organ injury. Normalization of platelets: First occurrence of normal platelet count (greater than or equal to \[\>=\]150,000/microliter \[mcL\]) that is followed by a confirmatory platelet count of \>=150,000/mcL and a lactate dehydrogenase (LDH) \<1.5×upper limit of normal (ULN) at 48±12 hours after the first occurrence.
Time frame: Through study completion, approximately 12 weeks
Part 2: Achievement of Platelet Response Without On-Study Plasma Exchange (PEX)
Platelet response is defined as first occurrence of normal platelet count (\>=150,000/mcL) that is followed by a confirmatory platelet count of \>=150,000/mcL at 48±12 hours after the first occurrence.
Time frame: Through study completion, approximately 12 weeks
Part 1: Achievement of Clinical Response With Zero or Minimal on-Study PEX
The number of PEX administered considered Zero when no PEX is administered and considered Minimal when 1 to 3 PEX are administered.
Time frame: Through study completion, approximately 12 weeks
Part 2: Achievement of Platelet Response With Zero or Minimal on-Study PEX
The number of PEX administered considered Zero when no PEX is administered and considered Minimal when 1 to 3 PEX are administered.
Time frame: Through study completion, approximately 12 weeks
Part 1: Achievement of Clinical Response Overall
Overall indicates clinical response regardless of whether on-study PEX is administered, or the number of PEX administered.
Time frame: Through study completion, approximately 12 weeks
Part 2: Achievement of Platelet Response Overall
Overall indicates platelet response regardless of whether on-study PEX is administered, or the number of PEX administered.
Time frame: Through study completion, approximately 12 weeks
Part 1: Time to Clinical Response (Acute Phase)
Time frame: Through study completion, approximately 12 weeks
Part 2: Time to Platelet Response (Acute Phase)
Time frame: Through study completion, approximately 12 weeks
Part 1: Occurrence of Refractoriness (Acute Phase)
Time frame: Through study completion, approximately 12 weeks
Part 1: Time to First On-Study PEX in Participants who Achieved Clinical Response
Time frame: Through study completion, approximately 12 weeks
Part 2: Time to First On-Study PEX in Participants who Achieved Platelet Response
Time frame: Through study completion, approximately 12 weeks
Part 1: Number of Days of On-study PEX in Participants to Achieve Clinical Response (Acute Phase)
Time frame: Through study completion, approximately 12 weeks
Part 2: Number of Days of On-study PEX in Participants to Achieve Platelet Response (Acute Phase)
Time frame: Through study completion, approximately 12 weeks
Part 1: Total Volume of Plasma Administered (Acute Phase) to Achieve Clinical Response
Time frame: Through study completion, approximately 12 weeks
Part 2: Total Volume of Plasma Administered (Acute Phase) to Achieve Platelet Response
Time frame: Through study completion, approximately 12 weeks
Part 1: Occurrence of Treatment Failure
Treatment failure is defined as failure to achieve clinical response, or experience iTTP recurrence.
Time frame: Through study completion, approximately 12 weeks
Part 2: Occurrence of Treatment Failure
Treatment failure is defined as failure to achieve platelet response, or experience iTTP recurrence.
Time frame: Through study completion, approximately 12 weeks
Part 1: Occurrence of Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) Recurrence (Following Clinical Response), Exacerbation, or Relapse (Post-acute Phase)
iTTP recurrence comprised of exacerbation or relapse. Clinical exacerbation: Occurs \<30 days after achieving initial clinical response (i.e., before clinical remission) and recurrent thrombocytopenia (platelet levels \<150,000/μL), with or without clinical evidence of new or progressive ischemic organ damage, requiring daily PEX or rescue therapy. Clinical relapses: Occurs \>=30 days after achieving initial clinical response (i.e., after clinical remission) and recurrent thrombocytopenia (platelet levels \<150,000/μL), with or without clinical evidence of new or progressive ischemic organ damage, requiring daily PEX or rescue therapy.
Time frame: Through study completion, approximately 12 weeks
Part 2: Occurrence of iTTP Recurrence (Following Platelet Response), Exacerbation, or Relapse (Post-acute Phase)
iTTP recurrence comprised of exacerbation or relapse. Clinical exacerbation: Occurs \<30 days after achieving initial platelet response (i.e., before clinical remission) and recurrent thrombocytopenia (platelet levels \<150,000/μL), with or without clinical evidence of new or progressive ischemic organ damage, requiring daily PEX or rescue therapy. Clinical relapses: Occurs \>=30 days after achieving initial platelet response (i.e., after clinical remission) and recurrent thrombocytopenia (platelet levels \<150,000/μL), with or without clinical evidence of new or progressive ischemic organ damage, requiring daily PEX or rescue therapy.
Time frame: Through study completion, approximately 12 weeks
Part 1: Time to iTTP Recurrence (Following Clinical Response), Exacerbation, or Relapse
Time frame: Through study completion, approximately 12 weeks
Part 2: Time to iTTP Recurrence (Following Platelet Response), Exacerbation, or Relapse
Time frame: Through study completion, approximately 12 weeks
Part 1: Occurrence of Any One of the Following Events: Clinical Recurrence (Following Clinical Response), iTTP-Related Death, or Major Thrombotic Event From Time of First IP Administration Through Study Completion
Time frame: Through study completion, approximately 12 weeks
Part 2: Occurrence of Any One of the Following Events: Clinical Recurrence (Following Platelet Response), iTTP-Related Death, or Major Thrombotic Event From Time of First IP Administration Through Study Completion
Time frame: Through study completion, approximately 12 weeks
Part 1: Time to Occurrence of Any One of the Following Events: Clinical Recurrence (Following Clinical Response), iTTP-Related Death, or Major Thrombotic Event From Time of First IP Administration Through Study Completion
Time frame: Through study completion, approximately 12 weeks
Part 2: Time to Occurrence of Any One of the Following Events: Clinical Recurrence (Following Platelet Response), iTTP-Related Death, or Major Thrombotic Event From Time of First IP Administration Through Study Completion
Time frame: Through study completion, approximately 12 weeks
Part 1: Change From Baseline in Lactate Dehydrogenase [LDH] Levels at Clinical Response and Study Completion
Time frame: Through study completion, approximately 12 weeks
Part 2: Change From Baseline in LDH Levels at Platelet Response and Study Completion
Time frame: Through study completion, approximately 12 weeks
Part 1: Change From Baseline in Troponin Levels at Clinical Response and Study Completion
Time frame: Through study completion, approximately 12 weeks
Part 2: Change From Baseline in Troponin Levels at Platelet Response and Study Completion
Time frame: Through study completion, approximately 12 weeks
Part 1: Achievement of Clinical Remission
Clinical remission is defined as achieving clinical response and no recurrence for \>=30 days.
Time frame: Through study completion, approximately 12 weeks
Part 2: Achievement of Clinical Remission
Clinical remission is defined as achieving platelet response and no recurrence for \>=30 days.
Time frame: Through study completion, approximately 12 weeks
Part 1 and 2: A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13 (ADAMTS13) Antigen Level Resulting From TAK-755 Administration in Acute and Post-Acute Phases
Time frame: Through study completion, approximately 12 weeks
Part 1 and 2: ADAMTS13 Activity Level Resulting From TAK-755 Administration in Acute and Post-Acute Phases
Time frame: Through study completion, approximately 12 weeks
Part 1: Von Willebrand Factor (VWF) Antigen Level Resulting From TAK-755 Administration in Acute and Post-Acute Phases
Time frame: Through study completion, approximately 12 weeks
Part 1: VWF Activity Level Resulting From TAK-755 Administration in Acute and Post-Acute Phases
Time frame: Through study completion, approximately 12 weeks
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: NOTE: IPD Sharing Time Frame has not been entered.
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement
Data sharing details ↗ · vivli.org
Ran from Jul 2023 to primary completion in Apr 2026, 32 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apadamtase alfa
Purpura, Thrombotic Thrombocytopenic →